Peter Altevogt

24.6k total citations · 6 hit papers
243 papers, 18.7k citations indexed

About

Peter Altevogt is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Peter Altevogt has authored 243 papers receiving a total of 18.7k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Molecular Biology, 85 papers in Immunology and 79 papers in Oncology. Recurrent topics in Peter Altevogt's work include Cell Adhesion Molecules Research (67 papers), Glycosylation and Glycoproteins Research (49 papers) and Monoclonal and Polyclonal Antibodies Research (45 papers). Peter Altevogt is often cited by papers focused on Cell Adhesion Molecules Research (67 papers), Glycosylation and Glycoproteins Research (49 papers) and Monoclonal and Polyclonal Antibodies Research (45 papers). Peter Altevogt collaborates with scholars based in Germany, Israel and United States. Peter Altevogt's co-authors include Sascha Keller, Alexander Stoeck, Mina Fogel, Jochen Utikal, Paul Gutwein, Rebekka Weber, Marei Sammar, Christopher Groth, Michael P. Sanderson and Glen Kristiansen and has published in prestigious journals such as Nature, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Peter Altevogt

239 papers receiving 18.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exosomes: From biogenesis and secretion to biological function

2006 713 citations Alexander Stoeck, Peter Altevogt et al. profile →
Body fluid derived exosomes as a novel template for clinical diagnostics

2011 621 citations Peter Altevogt et al. profile →
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression

2018 614 citations Christopher Groth, Xiaoying Hu et al. profile →
Interaction and uptake of exosomes by ovarian cancer cells

2011 530 citations Peter Altevogt, Júlia Costa et al. profile →
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

2018 406 citations Rebekka Weber, Viktor Fleming et al. profile →
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression

2018 355 citations Viktor Fleming, Xiaoying Hu et al. profile →

Peers

Countries citing papers authored by Peter Altevogt

Since Specialization

Citations

This map shows the geographic impact of Peter Altevogt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Altevogt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Altevogt more than expected).

Fields of papers citing papers by Peter Altevogt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Altevogt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Altevogt. The network helps show where Peter Altevogt may publish in the future.

Co-authorship network of co-authors of Peter Altevogt

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Altevogt. A scholar is included among the top collaborators of Peter Altevogt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Altevogt. Peter Altevogt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The emerging role of human transmembrane RGD-based counter-receptors of integrins in health and disease 2025 ·Cellular & Molecular Biology Letters ·Carlos Cabañas, Elisa Rossi, Rubén A. Bartolomé, Kai Doberstein, Peter Altevogt, J. Ignacio Casal, Carmelo Bernabéu	0
2	CD24 targeting with NK‐CAR immunotherapy in testis, prostate, renal and (luminal‐type) bladder cancer and identification of direct CD24 interaction partners 2023 ·FEBS Journal ·(unknown), David Thomas, Margaretha A. Skowron, Felix Bremmer, Markus Eckstein, Anja Stefanski, Marc D. Drießen, (unknown), Kai Stühler, Peter Altevogt, Dan Theodorescu, Rüdiger Klapdor, Axel Schambach, Daniel Nettersheim	9
3	STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice 2022 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Feyza Gül Özbay Kurt, Carolina De La Torre, Samantha Lasser, (unknown), (unknown), Verena Müller, Peter Altevogt, Jochen Utikal, Viktor Umansky	56
4	HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling 2022 ·Journal for ImmunoTherapy of Cancer ·Ihor Arkhypov, Feyza Gül Özbay Kurt, (unknown), Daniel Novak, Vera Petrova, Samantha Lasser, Thomas Hielscher, Christopher Groth, (unknown), Xiaoying Hu, Wei Li, Jochen Utikal, Peter Altevogt, Viktor Umansky	32
5	Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression 2021 ·Cancers ·Christopher Groth, Ludovica Arpinati, Merav E. Shaul, (unknown), (unknown), Nicolas Gengenbacher, Rebekka Weber, Ihor Arkhypov, Samantha Lasser, Vera Petrova, Hellmut G. Augustin, Peter Altevogt, Jochen Utikal, Zvi G. Fridlender, Viktor Umansky	24
6	The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas 2021 ·Molecular Oncology ·Margaretha A. Skowron, (unknown), (unknown), Sina Jostes, Felix Bremmer, Florian Fronhoffs, (unknown), (unknown), Melanie Müller, (unknown), Thomas Lenz, Anja Stefanski, Kai Stühler, Patrick Petzsch, Karl Köhrer, Peter Altevogt, Peter Albers, Glen Kristiansen, Hubert Schorle, Daniel Nettersheim	14
7	miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells 2021 ·Cancers ·(unknown), (unknown), Doreen Heckmann-Nötzel, Adam Kaczorowski, Markus Hohenfellner, Glen Kristiansen, Stefan Duensing, Peter Altevogt, Sabine M. Klauck, Holger Sültmann	8
8	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy 2020 ·Cellular Immunology ·Rebekka Weber, Christopher Groth, Samantha Lasser, Ihor Arkhypov, Vera Petrova, Peter Altevogt, Jochen Utikal, Viktor Umansky	219
9	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling 2019 ·Cancer Research ·Viktor Fleming, Xiaoying Hu, (unknown), Rebekka Weber, Christopher Groth, Zeno Riester, Laura Hüser, Qian Sun, Vasyl S. Nagibin, Carsten J. Kirschning, Vincenzo Bronte, Jochen Utikal, Peter Altevogt, Viktor Umansky	110
10	CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions 2018 ·Cancer Research ·C Blattner, Viktor Fleming, Rebekka Weber, (unknown), Peter Altevogt, Christoffer Gebhardt, Torsten J. Schulze, Hila Razon, (unknown), Gizi Wildbaum, Jochen Utikal, Nathan Karin, Viktor Umansky	151
11	Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions 2014 ·Clinical Cancer Research ·Matthias Piesche, Vincent T. Ho, Haesook Kim, Yukoh Nakazaki, (unknown), Nasser K. Yaghi, Dmitriy Kolodin, (unknown), Peter Altevogt, Helena Kiefel, Edwin P. Alyea, Joseph H. Antin, Corey Cutler, John Koreth, Christine Canning, Jerome Ritz, Robert J. Soiffer, Glenn Dranoff	10
12	Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell–Activating Receptor NKp30 2014 ·Cancer Research ·Eva Schlecker, Nathalie Fiegler, Annette Arnold, Peter Altevogt, Stefan Rose‐John, Gerhard Moldenhauer, Antje Sucker, Annette Paschen, Elke Pogge von Strandmann, Sonja Textor, Adelheid Cerwenka	169
13	Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice 2012 ·Gastroenterology ·(unknown), Charlotte Servais, Tova Waks, Markus Chmielewski, Ron Lavy, Peter Altevogt, Hinrich Abken, Zelig Eshhar	86
14	E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer 2010 ·Cancer Research ·Daniel Reimer, Michael Hubalek, Svenja Riedle, Sergej Skvortsov, Martin Erdel, Nicole Concin, Heidi Fiegl, Elisabeth Müller‐Holzner, Christian Marth, Karl Illmensee, Peter Altevogt, Alain G. Zeimet	30
15	Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma 2010 ·Cancer Research ·Silke Wolterink, Gerhard Moldenhauer, Mina Fogel, Helena Kiefel, Marco Pfeifer, (unknown), Ricardo M. Gouveia, Júlia Costa, Jan Endell, Ulrich Moebius, Peter Altevogt	60
16	Up-regulation of L1CAM in Pancreatic Duct Cells Is Transforming Growth Factor β1– and Slug-Dependent: Role in Malignant Transformation of Pancreatic Cancer 2009 ·Cancer Research ·Claudia Geismann, (unknown), Dorothee Koch, Frank Bergmann, Hendrik Ungefroren, Alexander Arlt, Ming‐Sound Tsao, Max G. Bachem, Peter Altevogt, Bence Sipos, Ulrich R. Fölsch, H. Schäfer, Susanne Sebens Müerköster	85
17	Lupeol Suppresses Cisplatin-Induced Nuclear Factor-κB Activation in Head and Neck Squamous Cell Carcinoma and Inhibits Local Invasion and Nodal Metastasis in an Orthotopic Nude Mouse Model 2007 ·Cancer Research ·Terence K. Lee, Ronnie T.P. Poon, Jana Y. Wo, Stephanie Ma, Xin‐Yuan Guan, Jeffrey N. Myers, Peter Altevogt, Anthony P.W. Yuen	90
18	Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas 2006 ·International Journal of Oncology ·Chengwen Zhang, Alexander Marmé, Till Wenger, Paul Gutwein, Lutz Edler, Werner Rittgen, Klaus‐Michael Debatin, Peter Altevogt, Jürgen Mattern, Ingrid Herr	39
19	Brain development in mice lacking L1–L1 homophilic adhesion 2004 ·The Journal of Cell Biology ·Kyoko Itoh, Ling Cheng, Yoshimasa Kamei, Shinji Fushiki, Hiroyuki Kamiguchi, Paul Gutwein, Alexander Stoeck, Bernd Arnold, Peter Altevogt, Vance Lemmon	74
20	Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors 2004 ·Journal of Clinical Investigation ·Philipp Beckhove, Markus Feuerer, (unknown), Florian Schuetz, Carmen Choi, Nora Sommerfeldt, Jochen Schwendemann, (unknown), Peter Altevogt, G. Bastert, Volker Schirrmacher, Viktor Umansky	103

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact